<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Pivot, Xavier</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Adjuvant Trastuzumab for 6 versus 12 Months in Patients with Early Breast Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">The Finland Herceptin [FinHer] trial results and concerns about cardiac toxicity with trastuzumab provided the rationale for the Trastuzumab for 6 Months or 1 Year in Treating Women with Nonmetastatic Breast Cancer That Can Be Removed by Surgery [PHARE; NCT00381901] trial. The primary objective of this noninferiority trial was to compare the effect of 6 versus 12 months of adjuvant treatment with trastuzumab on disease-free survival in patients with HER2-positive early breast cancer.</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>